Abstract
The activity of a cell is governed by the signals it receives from the extracellular milieu, which are 'translated' into the appropriate biological output, such as activation, survival, proliferation, migration or differentiation. Signaling pathways are responsible for converting environmental cues into discrete intracellular events. The alteration of existing proteins by post-translational modification (PTM) is a key feature of signal-transduction pathways that allows the modulation of protein function. Research into PTMs has long been dominated by the investigation of protein phosphorylation; other PTMs, such as methylation of lysine and arginine residues, acetylation, and nitrosylation of thiol groups and tyrosine residues, have received comparatively little attention. This Review aims to present an overview of these PTMs, with an emphasis on their role in cells of the immune system.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637–650 (2011).
Oeckinghaus, A., Hayden, M.S. & Ghosh, S. Crosstalk in NF-κB signaling pathways. Nat. Immunol. 12, 695–708 (2011).
O'Shea, J.J. & Plenge, R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36, 542–550 (2012).
Müller, M.R. & Rao, A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 10, 645–656 (2010).
Black, J.C., Van Rechem, C. & Whetstine, J.R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48, 491–507 (2012).
Martin, C. & Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838–849 (2005).
Bossen, C., Mansson, R. & Murre, C. Chromatin topology and the regulation of antigen receptor assembly. Annu. Rev. Immunol. 30, 337–356 (2012).
Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K. & O'Shea, J.J. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu. Rev. Immunol. 30, 707–731 (2012).
Natoli, G. Maintaining cell identity through global control of genomic organization. Immunity 33, 12–24 (2010).
Cedar, H. & Bergman, Y. Epigenetics of haematopoietic cell development. Nat. Rev. Immunol. 11, 478–488 (2011).
Bedford, M.T. Arginine methylation at a glance. J. Cell Sci. 120, 4243–4246 (2007).
Zurita-Lopez, C.I., Sandberg, T., Kelly, R. & Clarke, S.G. Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming omega-NG-monomethylated arginine residues. J. Biol. Chem. 287, 7859–7870 (2012).
Bedford, M.T. et al. Arginine methylation inhibits the binding of proline-rich ligands to Src homology 3, but not WW, domains. J. Biol. Chem. 275, 16030–16036 (2000).
Levy, D. et al. Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat. Immunol. 12, 29–36 (2011).This paper identifies RelA (p65) as a substrate of the PKMT SETD6, which interferes with RelA-driven transcription, and demonstrates that SETD6-dependent methylation of RelA prevents its association with the transcriptional activator GLP.
Ea, C.K. & Baltimore, D. Regulation of NF-κB activity through lysine monomethylation of p65. Proc. Natl. Acad. Sci. USA 106, 18972–18977 (2009).
Lu, T. et al. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc. Natl. Acad. Sci. USA 107, 46–51 (2010).
Lu, T. et al. Role of lysine methylation of NF-κB in differential gene regulation. Proc. Natl. Acad. Sci. USA 110, 13510–13515 (2013).
Yang, J. et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc. Natl. Acad. Sci. USA 107, 21499–21504 (2010).
Blanchet, F., Cardona, A., Letimier, F.A., Hershfield, M.S. & Acuto, O. CD28 costimulatory signal induces protein arginine methylation in T cells. J. Exp. Med. 202, 371–377 (2005).This report demonstrates that methylation of arginine is induced downstream of coligation of the TCR and CD28.
Fathman, J.W. et al. NIP45 controls the magnitude of the type 2 T helper cell response. Proc. Natl. Acad. Sci. USA 107, 3663–3668 (2010).
Mowen, K.A., Schurter, B.T., Fathman, J.W., David, M. & Glimcher, L.H. Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol. Cell 15, 559–571 (2004).
Infantino, S. et al. Arginine methylation of the B cell antigen receptor promotes differentiation. J. Exp. Med. 207, 711–719 (2010).
Stark, G.R. & Darnell, J.E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012).
Abramovich, C., Yakobson, B., Chebath, J. & Revel, M. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J. 16, 260–266 (1997).
Müller, P., Kuttenkeuler, D., Gesellchen, V., Zeidler, M.P. & Boutros, M. Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436, 871–875 (2005).
Pollack, B.P. et al. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity. J. Biol. Chem. 274, 31531–31542 (1999).
Mowen, K.A. et al. Arginine methylation of STAT1 modulates IFNα/β-induced transcription. Cell 104, 731–741 (2001).
Komyod, W., Bauer, U.M., Heinrich, P.C., Haan, S. & Behrmann, I. Are STATS arginine-methylated? J. Biol. Chem. 280, 21700–21705 (2005).
Rho, J., Choi, S., Seong, Y.R., Choi, J. & Im, D.S. The arginine-1493 residue in QRRGRTGR1493G motif IV of the hepatitis C virus NS3 helicase domain is essential for NS3 protein methylation by the protein arginine methyltransferase 1. J. Virol. 75, 8031–8044 (2001).
Chen, W., Daines, M.O. & Hershey, G.K. Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity. J. Immunol. 172, 6744–6750 (2004).
Iwasaki, H. et al. Disruption of protein arginine N-methyltransferase 2 regulates leptin signaling and produces leanness in vivo through loss of STAT3 methylation. Circ. Res. 107, 992–1001 (2010).
Duong, F.H., Filipowicz, M., Tripodi, M., La Monica, N. & Heim, M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126, 263–277 (2004).
Chen, D. et al. Regulation of transcription by a protein methyltransferase. Science 284, 2174–2177 (1999).
Lee, Y.H. & Stallcup, M.R. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol. Endocrinol. 23, 425–433 (2009).
Covic, M. et al. Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-κB -dependent gene expression. EMBO J. 24, 85–96 (2005).This paper shows that CARM1 acts to regulate the expression of genes encoding inflammatory molecules.
Anderson, P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat. Rev. Immunol. 10, 24–35 (2010).
Li, H. et al. Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J. Biol. Chem. 277, 44623–44630 (2002).
Yadav, N. et al. Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc. Natl. Acad. Sci. USA 100, 6464–6468 (2003).
Li, J. et al. Coactivator-associated arginine methyltransferase 1 regulates fetal hematopoiesis and thymocyte development. J. Immunol. 190, 597–604 (2013).
Kuo, A.J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609–620 (2011).
Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211–220 (2011).
McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).This article demonstrates the inhibition of mutant oncogenic EZH2 proteins through the use of selective inhibitors, which suggests a potential therapeutic strategy for some malignancies.
Chung, J. et al. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing. J. Biol. Chem. 288, 35534–35547 (2013).
Pal, S. et al. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 26, 3558–3569 (2007).
Wang, L., Pal, S. & Sif, S. Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol. Cell. Biol. 28, 6262–6277 (2008).
Liu, F. et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19, 283–294 (2011).
Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480–488 (2013).
Cheung, N., Chan, L.C., Thompson, A., Cleary, M.L. & So, C.W. Protein arginine-methyltransferase-dependent oncogenesis. Nat. Cell Biol. 9, 1208–1215 (2007).This paper shows that fusion of PRMT1 to MLL is sufficient to drive malignancy.
O'Brien, K.B. et al. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development 137, 2147–2156 (2010).
Vossenaar, E.R., Zendman, A.J., van Venrooij, W.J. & Pruijn, G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25, 1106–1118 (2003).
György, B., Toth, E., Tarcsa, E., Falus, A. & Buzas, E.I. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell Biol. 38, 1662–1677 (2006).
Méchin, M.C. et al. Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. Int. J. Cosmet. Sci. 29, 147–168 (2007).
Arita, K. et al. Structural basis for Ca2+-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11, 777–783 (2004).
Nakayama-Hamada, M. et al. Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem. Biophys. Res. Commun. 327, 192–200 (2005).
Foulquier, C. et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 56, 3541–3553 (2007).
Arandjelovic, S., McKenney, K.R., Leming, S.S. & Mowen, K.A. ATP induces protein arginine deiminase 2-dependent citrullination in mast cells through the P2X7 purinergic receptor. J. Immunol. 189, 4112–4122 (2012).
Lee, H.J. et al. Peptidylarginine deiminase 2 suppresses inhibitory κB kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages. J. Biol. Chem. 285, 39655–39662 (2010).
Perkins, N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol. 8, 49–62 (2007).
Kono, H. & Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279–289 (2008).
Atarashi, K. et al. ATP drives lamina propria TH17 cell differentiation. Nature 455, 808–812 (2008).
Lister, M.F. et al. The role of the purinergic P2X7 receptor in inflammation. J. Inflamm. (Lond.) 4, 5 (2007).
Flannagan, R.S., Cosio, G. & Grinstein, S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat. Rev. Microbiol. 7, 355–366 (2009).
Nauseef, W.M. How human neutrophils kill and degrade microbes: an integrated view. Immunol. Rev. 219, 88–102 (2007).
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532–1535 (2004).
Hemmers, S., Teijaro, J.R., Arandjelovic, S. & Mowen, K.A. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS ONE 6, e22043 (2011).
Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853–1862 (2010).This is the first paper to demonstrate that PAD4 is essential for NET formation.
Wang, Y. et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184, 205–213 (2009).
Buono, C. et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 102, 1596–1601 (2005).
Klareskog, L., Ronnelid, J., Lundberg, K., Padyukov, L. & Alfredsson, L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651–675 (2008).
Garcia-Romo, G.S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).
Crome, S.Q., Wang, A.Y. & Levings, M.K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 159, 109–119 (2010).
Kidd, B.A. et al. Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res. Ther. 10, R119 (2008).
Wood, D.D. et al. Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab. Invest. 88, 354–364 (2008).
Moscarello, M.A., Pritzker, L., Mastronardi, F.G. & Wood, D.D. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J. Neurochem. 81, 335–343 (2002).
Asaga, H., Akiyama, K., Ohsawa, T. & Ishigami, A. Increased and type II-specific expression of peptidylarginine deiminase in activated microglia but not hyperplastic astrocytes following kainic acid-evoked neurodegeneration in the rat brain. Neurosci. Lett. 326, 129–132 (2002).
Sambandam, T. et al. Increased peptidylarginine deiminase type II in hypoxic astrocytes. Biochem. Biophys. Res. Commun. 325, 1324–1329 (2004).
Akiyama, K., Sakurai, Y., Asou, H. & Senshu, T. Localization of peptidylarginine deiminase type II in a stage-specific immature oligodendrocyte from rat cerebral hemisphere. Neurosci. Lett. 274, 53–55 (1999).
Musse, A.A. et al. Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system. Dis Model Mech 1, 229–240 (2008).
Raijmakers, R. et al. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J. Comp. Neurol. 498, 217–226 (2006).
Masson-Bessière, C. et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J. Immunol. 166, 4177–4184 (2001).This study shows that the autoantibodies to keratin and filaggrin found in patients with RA recognize epitopes that contain citrulline.
Hill, J.A. et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J. Exp. Med. 205, 967–979 (2008).
Kuhn, K.A. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961–973 (2006).
Lundberg, K. et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7, R458–R467 (2005).
Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395–402 (2003).This article identifies PADI4 as a gene linked to susceptibility to RA.
Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 1336–1340 (2012).
Zhao, X. et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res. Ther. 10, R94 (2008).
Yoshida, M. et al. Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod. Rheumatol. 16, 276–281 (2006).
Jones, J.E., Causey, C.P., Knuckley, B., Slack-Noyes, J.L. & Thompson, P.R. Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr. Opin. Drug Discov. Devel. 12, 616–627 (2009).
Dwivedi, N. et al. Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps. Arthritis Rheum. 64, 982–992 (2012).
Förstermann, U. et al. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem. Pharmacol. 42, 1849–1857 (1991).
Benhar, M., Forrester, M.T. & Stamler, J.S. Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat. Rev. Mol. Cell Biol. 10, 721–732 (2009).
Choi, Y.B. et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 3, 15–21 (2000).
Uehara, T. et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441, 513–517 (2006).
Doulias, P.T. et al. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. Proc. Natl. Acad. Sci. USA 107, 16958–16963 (2010).
Yang, Y., Fang, S., Jensen, J.P., Weissman, A.M. & Ashwell, J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874–877 (2000).
Nakamura, T. et al. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol. Cell 39, 184–195 (2010).This paper demonstrates that NO reacts with XIAP by S-nitrosylating its RING domain, which inhibits its E3 ligase and antiapoptotic activity.
Hara, M.R. et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol. 7, 665–674 (2005).
Ryu, I.H. & Do, S.I. Denitrosylation of S-nitrosylated OGT is triggered in LPS-stimulated innate immune response. Biochem. Biophys. Res. Commun. 408, 52–57 (2011).
Seth, D. & Stamler, J.S. The SNO-proteome: causation and classifications. Curr. Opin. Chem. Biol. 15, 129–136 (2011).
MacMillan-Crow, L.A. & Thompson, J.A. Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch. Biochem. Biophys. 366, 82–88 (1999).
Redondo-Horcajo, M. et al. Cyclosporine A-induced nitration of tyrosine 34 MnSOD in endothelial cells: role of mitochondrial superoxide. Cardiovasc. Res. 87, 356–365 (2010).
Llovera, M., Pearson, J.D., Moreno, C. & Riveros-Moreno, V. Impaired response to interferon-γ in activated macrophages due to tyrosine nitration of STAT1 by endogenous nitric oxide. Br. J. Pharmacol. 132, 419–426 (2001).
Birnboim, H.C., Lemay, A.M., Lam, D.K., Goldstein, R. & Webb, J.R. Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J. Immunol. 171, 528–532 (2003).
Herzog, J., Maekawa, Y., Cirrito, T.P., Illian, B.S. & Unanue, E.R. Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells. Proc. Natl. Acad. Sci. USA 102, 7928–7933 (2005).
Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828–835 (2007).
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
Haberland, M., Montgomery, R.L. & Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32–42 (2009).
Chi, H. & Flavell, R.A. Acetylation of MKP-1 and the control of inflammation. Sci. Signal. 1, pe44 (2008).
Chang, H.M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. USA 101, 9578–9583 (2004).
Munshi, N. et al. Acetylation of HMG I(Y) by CBP turns off IFN β expression by disrupting the enhanceosome. Mol. Cell 2, 457–467 (1998).
Chen, L.F., Mu, Y. & Greene, W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J. 21, 6539–6548 (2002).
Nusinzon, I. & Horvath, C.M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. USA 100, 14742–14747 (2003).
Krämer, O.H. et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20, 473–485 (2006).
Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280, 11528–11534 (2005).
Yuan, Z.L., Guan, Y.J., Chatterjee, D. & Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269–273 (2005).This paper demonstrates that STAT3 is regulated by acetylation of its lysine residues.
Bresnick, E.H., Lee, H.Y., Fujiwara, T., Johnson, K.D. & Keles, S. GATA switches as developmental drivers. J. Biol. Chem. 285, 31087–31093 (2010).
Dengler, H.S. et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9, 1388–1398 (2008).
Kerdiles, Y.M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176–184 (2009).
Kerdiles, Y.M. et al. Foxo transcription factors control regulatory T cell development and function. Immunity 33, 890–904 (2010).
Hayakawa, F. et al. Functional regulation of GATA-2 by acetylation. J. Leukoc. Biol. 75, 529–540 (2004).
Yamagata, T. et al. Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J. 19, 4676–4687 (2000).
Calnan, D.R. & Brunet, A. The FoxO code. Oncogene 27, 2276–2288 (2008).
Uhlmann, T. et al. A method for large-scale identification of protein arginine methylation. Mol. Cell. Proteomics 11, 1489–1499 (2012).
Acknowledgements
We thank J.M. Keith for assistance in preparing the figures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mowen, K., David, M. Unconventional post-translational modifications in immunological signaling. Nat Immunol 15, 512–520 (2014). https://doi.org/10.1038/ni.2873
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2873